About
In a 90-day open label trial of 306 testosterone deficient men using two actuations (11mg) of the drug applied three times daily, results were reported for 73 men at day 90. It restores the circulating testosterone level to the physiological range. Testosterone patches consist of a mixture of testosterone, penetration agents, and a gelatinous matrix separated from the skin by a microporous membrane. Liquids and gels should be applied to clean, dry skin, and the treatment site should not be washed until the time of next application to optimize delivery. Although one objective of meta-analyses is to increase study power to identify significant results, this often results in an amalgamation of studies that may have different primary and secondary endpoints, thereby reducing the reliability of the outcomes. It also highlights that treating clinicians should have specific endpoints for treatment in mind, with regular monitoring of these outcomes to assure that ongoing therapy is warranted and effective.It is possible that exercise programs coupled with diet may have a greater likelihood of success in achieving increases in total testosterone over calorie-restricted diets alone. Increases in testosterone for patients who lose weight might be cumulative over time. A discussion regarding the benefit of stopping testosterone therapy should include the possibility of a decline in PSA. PSA recurrence in men on testosterone therapy should be evaluated in the same fashion as untreated men. There are limited data in men on active surveillance who are candidates for testosterone therapy.
The most accurate testosterone measurements are obtained in the early morning and on more than one occasion, which is not uniform across testosterone trials. Clinicians wishing to identify laboratories meeting CDC standards are encouraged to refer to the list of sites currently meeting CDC requirements listed on the CDC Hormone Standardization Program. This situation commonly occurs as reference laboratories often define a normal value as ranging within the 5th (or 2.5th) and 95th (or 97.5th) percentiles of a sampled population.
The manufacturer-recommended dosing of IM testosterone undecanoate is 750 mg administered at weeks 0, 4, and every 10 weeks thereafter. No RCTs have compared the current formulation of IM testosterone undecanoate available in the United States to other therapies. Testosterone undecanoate is the only currently available long-acting injection therapy available as a 750 mg (3 mL) preparation and must be administered in the office under supervision. The optimal dosing strategy has not been defined for short-acting IM testosterone preparations. The half-life for IM testosterone was also shorter at 173 hours versus 240 hours for SQ testosterone. Although IM injections are the traditional route for injectable agents, the SQ route has also been described with short-acting agents.437 Injectable testosterone is available in several forms, including short acting and long-acting preparations.
Most studies assessing hCG efficacy have been performed in males with congenital/idiopathic hypogonadotropic hypogonadism.397, 398 While the literature regarding hCG use in adult males with symptomatic testosterone deficiency is less robust, several important reports are worth discussing. These agents share the common overall treatment effect of increasing intrinsic production of testosterone, but there are substantial differences in pharmacologic characteristics and mechanisms of action between them. It is approved in some countries for treatment of testosterone deficiency but is not currently approved in the US. Methyltestosterone is an oral androgen modified at the 17-alpha position resulting in decreased first pass hepatic clearance and is approved in the US for treatment of testosterone deficiency. While some patients may continue to experience symptom/sign relief after this time point, the majority of men have meaningful improvements within the first three months of therapy.